Alisa B. Lee‐Sherick

Author

University of Colorado Anschutz Medical Campus ORCID

Also Known As

A B Lee-Sherick, A.B. Lee‐Sherick, Alisa B Lee-Sherick, Alisa B. Lee, Alisa B. Lee-Sherick, Alisa B. Lee‐Sherick, Alisa Lee Sherick, Alisa Lee-Sherick, Kireev, Dmitri, Rupji, Manali

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Anschutz Medical Campus University of North Carolina at Chapel Hill University of Colorado Denver Emory University UNC Lineberger Comprehensive Cancer Center

About

Alisa B. Lee‐Sherick is an author at University of Colorado Anschutz Medical Campus specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	539
2	Cell Biology	4	4	498
3	Immunology	2	2	146
4	Pathology	2	2	363
5	Microbiology	1	1	41

Alisa B. Lee‐Sherick

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia Leila Noetzli, Richard Lo, Alisa B. Lee‐Sherick, Nature Genetics Hematological MalignancyMedicinePathogenesisHematologyPathology	2015	322
The unexpected effect of cyclosporin A on CD56+CD16− and CD56+CD16+ natural killer cell subpopulations Hongbo Wang, Bartosz Grzywacz, David J. Sukovich, Blood	2007	134
Promoter Specificity and Efficacy in Conditional and Inducible Transgenic Targeting of Lung Macrophages Alexandra L. McCubbrey, Kristen C. Allison, Alisa B. Lee‐Sherick, Frontiers in Immunology	2017	105
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia Alisa B. Lee‐Sherick, K M Eisenman, Susan Sather, Oncogene	2013	102
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, JCI Insight Fms-like Tyrosine KinaseMixed-phenotype Acute LeukemiaResistance-conferring Flt3 MutationsImmunologyTumor Biology	2016	75
UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models Deborah DeRyckere, Alisa B. Lee‐Sherick, Madeline G. Huey, Clinical Cancer Research	2016	71
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry, JCI Insight Hematological MalignancyHost MertkCancer ImmunosurveillanceMalignant Blood DisorderImmunology	2018	71
Mer receptor tyrosine kinase is a therapeutic target in pre–B-cell acute lymphoblastic leukemia Rachel M.A. Linger, Alisa B. Lee‐Sherick, Deborah DeRyckere, Blood	2013	62
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia Alisa B. Lee‐Sherick, Weihe Zhang, Kelly Menachof, Oncotarget	2015	42
Bacterial meningitis from <i>Rothia mucilaginosa</i> in patients with malignancy or undergoing hematopoietic stem cell transplantation Alisa B. Lee‐Sherick, Paul Harker‐Murray, Patricia Ferrieri, Pediatric Blood & Cancer Bacterial InfectionsMicrobial DiseaseAntibioticsFatal MeningitisHealthcare-associated Infection	2007	41

Page 1